Alaunos Therapeutics, Inc. (TCRT) stock
Close on Nov 18, 2026Market cap $4.37MP/E –Yield –
Earnings
Alaunos Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Alaunos Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2024ended Sep 30, 2024 | Oct 10, 2024before the open | – | – | – | Filing |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | $0 | -100.0% | -$0.04 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | $4.00K | – | -$0.04 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023before the open | – | – | -$0.04 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 7, 2023before the open | $11.00K | – | -$0.04 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | $2.90M | – | -$0.04 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | – | – | -$0.05 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | -$0.05 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 30, 2022before the open | – | – | -$0.05 | Release |
| Q1 FY2021ended Jun 30, 2021 | Aug 9, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 5, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 7, 2019after the close | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 8, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 8, 2019after the close | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 5, 2019after the close | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 8, 2018after the close | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 10, 2018after the close | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Mar 1, 2018after the close | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 6, 2017after the close | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Jul 31, 2017after the close | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | May 1, 2017after the close | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Feb 16, 2017after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Alaunos Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| operating outflows, excluding debt service costs | FY2023 | $35.00M – $40.00M | – | New | Mar 7, 2023 |
Guidance history
Every forecast Alaunos Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Mar 7, 2023 | operating outflows, excluding debt service costs | FY2023 | $35.00M – $40.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Alaunos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- News
- News
- News
- Results
- Results
- Results
- Results
- Update
- Update
- News
See a number that looks wrong?